HOME > Investors > Press Releases
2016-01-25
ViroMed reports operating profit increased by 342% from previous year
2016-01-22
ViroMed Publishes Results from Critical Limb Ischemia (CLI) Phase II Clinical Study
2016-01-21
Texas Heart Institute announces PAD phase II results on "Gene Therapy"
2015-12-04
ViroMed and bluebird bio Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
2015-09-01
US FDA Approves VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer by US FDA
11 12 13 14 15 16 17 18 19 20